Table 5.
Predictors of mortality (medications) after hip fracture in AD and non-AD cohorts (persons with previous fractures excluded)
| Risk factor | Category | AD cohort | Non-AD cohort | ||||
|---|---|---|---|---|---|---|---|
| Mortality/ 100 PY | Unadjusted HR (95% CI) |
Adjusted HRa
(95% CI) |
Mortality/ 100 PY | Unadjusted HR (95% CI) |
Adjusted HRa
(95% CI) |
||
| Any CVD medication | Yes | 31.6 | 1.12 (1.03–1.22) | 1.18 (1.08–1.29) | 28.1 | 1.25 (1.02–1.54) | 1.28 (1.04–1.58) |
| No | 24.7 | 1.00 (reference) | 1.00 (reference) | 17.4 | 1.00 (reference) | 1.00 (reference) | |
| Yes | 30.0 | 1.17 (1.05–1.31) | 1.17 (1.04–1.31) | 24.0 | 1.36 (1.06–1.74) | 1.37 (1.07–1.76) | |
| Drugs for obstructive airway diseases | No | 28.3 | 1.00 (reference) | 1.00 (reference) | 23.1 | 1.00 (reference) | 1.00 (reference) |
| Yes | 35.3 | 1.25 (1.12–1.39) | 1.17 (1.05–1.30) | 24.3 | 1.04 (0.88–1.23) | 1.11 (0.94–1.32) | |
| Hormone therapy | No | 29.8 | 1.00 (reference) | 1.00 (reference) | 23.7 | 1.00 (reference) | 1.00 (reference) |
| Yes | 18.6 | 0.63 (0.49–0.80) | 0.81 (0.64–1.04) | 11.7 | 0.50 (0.29–0.85) | 0.78 (0.46–1.32) | |
| Bisphosphonates | No | 29.5 | 1.00 (reference) | 1.00 (reference) | 23.7 | 1.00 (reference) | 1.00 (reference) |
| Yes | 28.1 | 0.95 (0.85–1.07) | 1.07 (0.95–1.20) | 21.0 | 0.88 (0.72–1.06) | 1.06 (0.87–1.29) | |
| Proton pump inhibitors | No | 26.8 | 1.00 (reference) | 1.00 (reference) | 21.0 | 1.00 (reference) | 1.00 (reference) |
| Yes | 33.4 | 1.24 (1.15–1.35) | 1.25 (1.15–1.36) | 26.8 | 1.27 (1.12–1.45) | 1.31 (1.15–1.49) | |
| Anti–Parkinson drugs | No | 29.28 | 1.00 (reference) | 1.00 (reference) | 23.12 | 1.00 (reference) | 1.00 (reference) |
| Yes | 29.10 | 0.99 (0.84–1.18) | 1.02 (0.86–1.21) | 27.15 | 1.18 (0.91–1.54) | 1.20 (0.92–1.56) | |
| Antiepileptics drugs | No | 29.0 | 1.00 (reference) | 1.00 (reference) | 23.6 | 1.00 (reference) | 1.00 (reference) |
| Yes | 31.9 | 1.10 (0.96–1.25) | 1.12 (0.99–1.28) | 21.2 | 0.90 (0.72–1.11) | 0.98 (0.79–1.21) | |
| Antipsychotics | No | 28.2 | 1.00 (reference) | 1.00 (reference) | 22.3 | 1.00 (reference) | 1.00 (reference) |
| Yes | 31.1 | 1.10 (1.01–1.20) | 1.16 (1.06–1.26) | 30.9 | 1.41 (1.18–1.68) | 1.41 (1.18–1.68) | |
| Antidepressants | No | 30.7 | 1.00 (reference) | 1.00 (reference) | 22.1 | 1.00 (reference) | 1.00 (reference) |
| Yes | 27.5 | 0.89 (0.82–0.97) | 0.97 (0.89–1.05) | 26.9 | 1.22 (1.05–1.40) | 1.29 (1.11–1.48) | |
| BZDRS | No | 28.4 | 1.00 (reference) | 1.00 (reference) | 21.3 | 1.00 (reference) | 1.00 (reference) |
| Yes | 30.2 | 1.06 (0.98–1.15) | 1.06 (0.98–1.15) | 25.7 | 1.21 (1.06–1.38) | 1.18 (1.04–1.35) | |
| Opioids | No | 25.5 | 1.00 (reference) | 1.00 (reference) | 18.7 | 1.00 (reference) | 1.00 (reference) |
| Yes | 32.9 | 1.30 (1.20–1.41) | 1.29 (1.19–1.40) | 28.5 | 1.50 (1.31–1.72) | 1.56 (1.36–1.79) | |
aAdjusted for occupational social class